| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology, Medical College of Georgia, Augusta (Drs. Meador, Loring, Ray, Murro, and King); and Department of Neurology, New York University, New York (Drs. Perrine, Vazquez, and Kiolbasa).
Address correspondence and reprint requests to Dr. K.J. Meador, Department of Neurology, Medical College of Georgia, 1120 15th St. (BA3410), Augusta, GA 30912; e-mail: kmeador{at}neuro.mcg.edu
BACKGROUND: The relative cognitive and behavioral effects of lamotrigine compared with the older standard antiepileptic drugs (AED) are uncertain.
OBJECTIVE: To directly compare the cognitive and behavioral effects of carbamazepine and lamotrigine.
METHODS: The cognitive and behavioral effects of carbamazepine and lamotrigine were assessed in 25 healthy adults using a double-blind, randomized crossover design with two 10-week treatment periods. During each treatment condition, subjects received either lamotrigine (150 mg/day) or carbamazepine (mean 696 mg/day) adjusted to a dose to achieve midrange standard therapeutic blood levels (mean 7.6 µg/mL). Subjects were tested at the end of each AED treatment period and in three drug-free conditions (two pretreatment baselines and a final posttreatment period [1 month after last AED]). The neuropsychological test battery included 19 measures yielding 40 total variables.
RESULTS: Direct comparison of the two AED revealed significantly better performance on 19 (48%) variables for lamotrigine but none for carbamazepine. Differences spanned both objective cognitive and subjective behavioral measures, including cognitive speed, memory, graphomotor coding, neurotoxic symptoms, mood factors, sedation, perception of cognitive performance, and other quality-of-life perceptions. Comparison of carbamazepine with the nondrug average revealed significantly better performance for nondrug average on 24 (62%) variables but none for carbamazepine. Comparison of lamotrigine with nondrug average revealed better performance on one (2.5%) variable for nondrug average and on one (2.5%) variable for lamotrigine.
CONCLUSION: Lamotrigine produces significantly fewer untoward cognitive and behavioral effects than carbamazepine at the dosages used in this study.
This article has been cited by other articles:
|
|
 |
|
  J. O. Brooks and J. C. Hoblyn Neurocognitive Costs and Benefits of Psychotropic Medications in Older Adults J Geriatr Psychiatry Neurol, December 1, 2007; 20(4): 199 - 214. [Abstract] [PDF]
|
|
|
|
 |
|
 R. M. Pressler, C. D. Binnie, S. G. Coleshill, G. A. Chorley, and R. O. Robinson Effect of lamotrigine on cognition in children with epilepsy Neurology, May 23, 2006; 66(10): 1495 - 1499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Gilliam, J. Carter, and V. Vahle Tolerability of antiseizure medications: Implications for health outcomes Neurology, November 23, 2004; 63(10_suppl_4): S9 - S12. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. F. D. Bourgeois Determining the Effects of Antiepileptic Drugs on Cognitive Function in Pediatric Patients With Epilepsy J Child Neurol, August 1, 2004; 19(1_suppl): S15 - S24. [Abstract] [PDF]
|
|
|
|
|
|
B. F. D. Bourgeois Determining the Effects of Antiepileptic Drugs on Cognitive Function in Pediatric Patients With Epilepsy J Child Neurol, January 1, 2004; 19(1_suppl): S15 - S24. [Abstract] [PDF]
|
|
|
|
|
|
K. J. Meador, D. W. Loring, J. F. Hulihan, M. Kamin, and R. Karim Differential cognitive and behavioral effects of topiramate and valproate Neurology, May 13, 2003; 60(9): 1483 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Lathers, P. L. Schraeder, and H. G. Claycamp Clinical Pharmacology of Topiramate versus Lamotrigine versus Phenobarbital: Comparison of Efficacy and Side Effects Using Odds Ratios J. Clin. Pharmacol., May 1, 2003; 43(5): 491 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Diaz-Arrastia, M. A. Agostini, and P. C. Van Ness Evolving Treatment Strategies for Epilepsy JAMA, June 12, 2002; 287(22): 2917 - 2920. [Full Text] [PDF]
|
|
|
|
|
|
F. Gilliam Optimizing health outcomes in active epilepsy Neurology, April 23, 2002; 58(90085): S9 - 20. [Abstract] [Full Text]
|
|
|
|
|
|
K. J. Meador Cognitive outcomes and predictive factors in epilepsy Neurology, April 23, 2002; 58(90085): S21 - 26. [Abstract] [Full Text]
|
|
|
|
|
|
M. Duchowny, J. Gilman, J. Messenheimer, G. Womble, M. Risner, and Lamictal Pediatric Study Group Long-Term Tolerability and Efficacy of Lamotrigine in Pediatric Patients With Epilepsy J Child Neurol, April 1, 2002; 17(4): 278 - 285. [Abstract] [PDF]
|
|
|
|
|
|
B. F.D. Bourgeois Differential Cognitive Effects of Antiepileptic Drugs J Child Neurol, February 1, 2002; 17(2_suppl): 2S28 - 2S33. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
